Back to results
US 2020/0002398 A1Published application
De Novo Design of Potent and Selective Interleukin Mimetics
AssigneesUniversity of Washington, The Board of Trustees of the Leland Stanford Junior University
InventorsDaniel Adriano SILVA MANZANO, Shawn YU, Umut ULGE, David BAKER, Kenan Christopher GARCIA, Jamie SPANGLER, Carl WALKEY, Alfredo QUIJANO RUBIO
Life of this patent
Estimating the term…
Abstract
De novo designed polypeptides that bind to IL-2 receptor βγcheterodimer (IL-2Rβγc), IL-4 receptor αγcheterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
Claims31
-138. (canceled)
A non-naturally occurring polypeptide comprising domains X1, X2, X3, and X4, wherein:
- (a) X1 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to EHALYDAL (SEQ ID NO:1);
- (b) X2 is a helical-peptide of at least 8 amino acids in length;
- (c) X3 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to YAFNFELI (SEQ ID NO:2);
- (d) X4 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to ITILQSWIF (SEQ ID NO:3);
- wherein X1, X2, X3, and X4 may be in any order in the polypeptide;
- wherein amino acid linkers may be present between any of the domains;
- and
- wherein the polypeptide binds to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγcheterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα).
5 more elements
Dependencies are inferred from the claim text.